The systemic fibrinolytic activity of intrapleural streptokinase
Intrapleural fibrinolytics probably improve the drainage of loculated pleural effusions and empyemas. Studies of crude indices of systemic coagulation suggest this effect is accompanied by little systemic fibrinolysis, but few studies have assessed this in detail. This study examines the systemic fi...
Gespeichert in:
| Veröffentlicht in: | American journal of respiratory and critical care medicine 1998, Vol.157 (1), p.328-330 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 330 |
|---|---|
| container_issue | 1 |
| container_start_page | 328 |
| container_title | American journal of respiratory and critical care medicine |
| container_volume | 157 |
| creator | DAVIES, C. W. H LOK, S DAVIES, R. J. O |
| description | Intrapleural fibrinolytics probably improve the drainage of loculated pleural effusions and empyemas. Studies of crude indices of systemic coagulation suggest this effect is accompanied by little systemic fibrinolysis, but few studies have assessed this in detail. This study examines the systemic fibrinolytic activity of two intrapleural streptokinase (IPSK) regimes in detail. Eight patients received a single dose of 250,000 IU IPSK, and a further eight received serial doses of 250,000 IU IPSK every 12 h for 3 d (total dose: 1.5 million IU). Each dose was retained in the pleural cavity for 2 h. Venous blood for prothrombin time, activated partial thromboplastin time, thrombin time, fibrinogen, and D-dimers due to fibrin degradation were measured before any IPSK. These end points were then remeasured 24 h after IPSK in the single-dose group and after 24, 48, and 72 h in the group receiving serial doses. There were no physiologic or statistical differences in any of the indices after administration of IPSK. IPSK administered up to a dose of 1.5 million IU does not cause significant activation systemic fibrinolysis in humans. |
| doi_str_mv | 10.1164/ajrccm.157.1.97-03094 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79672000</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79672000</sourcerecordid><originalsourceid>FETCH-LOGICAL-c333t-ada7dfed8bea04df8773f007b8b65e82a046f4af27a1cf3eb33a8b5a0668d6603</originalsourceid><addsrcrecordid>eNo9kEtLAzEUhYMotVZ_QmEW4m7qzSSTzOyU4gsKbiq4C3cyCabOoyYZof_eqS1d3cc591z4CJlTWFAq-D1uvNbtguZyQRelTIFByc_IlOYsT3kp4XzsQbKU8_LzklyFsAGgWUFhQiYl5zmjYkoe1l8mCbsQTet0Yl3lXdc3uzgOqKP7dXGX9DZxXfS4bczgsUlC9GYb-2_XYTDX5MJiE8zNsc7Ix_PTevmart5f3paPq1QzxmKKNcramrqoDAKvbSElswCyKiqRmyIbl8JytJlEqi0zFWNYVDmCEEUtBLAZuTvkbn3_M5gQVeuCNk2DnemHoGQpZAawN-YHo_Z9CN5YtfWuRb9TFNSenDqQUyM5RVUp1T-58W5-fDBUralPV0dUo3571DFobKzHTrtwsmVjdJED-wPoWnn2</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79672000</pqid></control><display><type>article</type><title>The systemic fibrinolytic activity of intrapleural streptokinase</title><source>MEDLINE</source><source>American Thoracic Society (ATS) Journals Online</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Journals@Ovid Complete</source><creator>DAVIES, C. W. H ; LOK, S ; DAVIES, R. J. O</creator><creatorcontrib>DAVIES, C. W. H ; LOK, S ; DAVIES, R. J. O</creatorcontrib><description>Intrapleural fibrinolytics probably improve the drainage of loculated pleural effusions and empyemas. Studies of crude indices of systemic coagulation suggest this effect is accompanied by little systemic fibrinolysis, but few studies have assessed this in detail. This study examines the systemic fibrinolytic activity of two intrapleural streptokinase (IPSK) regimes in detail. Eight patients received a single dose of 250,000 IU IPSK, and a further eight received serial doses of 250,000 IU IPSK every 12 h for 3 d (total dose: 1.5 million IU). Each dose was retained in the pleural cavity for 2 h. Venous blood for prothrombin time, activated partial thromboplastin time, thrombin time, fibrinogen, and D-dimers due to fibrin degradation were measured before any IPSK. These end points were then remeasured 24 h after IPSK in the single-dose group and after 24, 48, and 72 h in the group receiving serial doses. There were no physiologic or statistical differences in any of the indices after administration of IPSK. IPSK administered up to a dose of 1.5 million IU does not cause significant activation systemic fibrinolysis in humans.</description><identifier>ISSN: 1073-449X</identifier><identifier>EISSN: 1535-4970</identifier><identifier>DOI: 10.1164/ajrccm.157.1.97-03094</identifier><identifier>PMID: 9445316</identifier><language>eng</language><publisher>New York, NY: American Lung Association</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Drainage ; Drug Monitoring ; Empyema, Pleural - drug therapy ; Empyema, Pleural - microbiology ; Female ; Fibrinolysis - drug effects ; Fibrinolytic Agents - therapeutic use ; Humans ; Male ; Medical sciences ; Middle Aged ; Partial Thromboplastin Time ; Pharmacology. Drug treatments ; Pleural Effusion - drug therapy ; Pleural Effusion - microbiology ; Pleurodesis ; Prothrombin Time ; Respiratory system ; Streptokinase - therapeutic use ; Thrombin Time</subject><ispartof>American journal of respiratory and critical care medicine, 1998, Vol.157 (1), p.328-330</ispartof><rights>1998 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c333t-ada7dfed8bea04df8773f007b8b65e82a046f4af27a1cf3eb33a8b5a0668d6603</citedby><cites>FETCH-LOGICAL-c333t-ada7dfed8bea04df8773f007b8b65e82a046f4af27a1cf3eb33a8b5a0668d6603</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,4010,4011,27900,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2116850$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9445316$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>DAVIES, C. W. H</creatorcontrib><creatorcontrib>LOK, S</creatorcontrib><creatorcontrib>DAVIES, R. J. O</creatorcontrib><title>The systemic fibrinolytic activity of intrapleural streptokinase</title><title>American journal of respiratory and critical care medicine</title><addtitle>Am J Respir Crit Care Med</addtitle><description>Intrapleural fibrinolytics probably improve the drainage of loculated pleural effusions and empyemas. Studies of crude indices of systemic coagulation suggest this effect is accompanied by little systemic fibrinolysis, but few studies have assessed this in detail. This study examines the systemic fibrinolytic activity of two intrapleural streptokinase (IPSK) regimes in detail. Eight patients received a single dose of 250,000 IU IPSK, and a further eight received serial doses of 250,000 IU IPSK every 12 h for 3 d (total dose: 1.5 million IU). Each dose was retained in the pleural cavity for 2 h. Venous blood for prothrombin time, activated partial thromboplastin time, thrombin time, fibrinogen, and D-dimers due to fibrin degradation were measured before any IPSK. These end points were then remeasured 24 h after IPSK in the single-dose group and after 24, 48, and 72 h in the group receiving serial doses. There were no physiologic or statistical differences in any of the indices after administration of IPSK. IPSK administered up to a dose of 1.5 million IU does not cause significant activation systemic fibrinolysis in humans.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Drainage</subject><subject>Drug Monitoring</subject><subject>Empyema, Pleural - drug therapy</subject><subject>Empyema, Pleural - microbiology</subject><subject>Female</subject><subject>Fibrinolysis - drug effects</subject><subject>Fibrinolytic Agents - therapeutic use</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Partial Thromboplastin Time</subject><subject>Pharmacology. Drug treatments</subject><subject>Pleural Effusion - drug therapy</subject><subject>Pleural Effusion - microbiology</subject><subject>Pleurodesis</subject><subject>Prothrombin Time</subject><subject>Respiratory system</subject><subject>Streptokinase - therapeutic use</subject><subject>Thrombin Time</subject><issn>1073-449X</issn><issn>1535-4970</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kEtLAzEUhYMotVZ_QmEW4m7qzSSTzOyU4gsKbiq4C3cyCabOoyYZof_eqS1d3cc591z4CJlTWFAq-D1uvNbtguZyQRelTIFByc_IlOYsT3kp4XzsQbKU8_LzklyFsAGgWUFhQiYl5zmjYkoe1l8mCbsQTet0Yl3lXdc3uzgOqKP7dXGX9DZxXfS4bczgsUlC9GYb-2_XYTDX5MJiE8zNsc7Ix_PTevmart5f3paPq1QzxmKKNcramrqoDAKvbSElswCyKiqRmyIbl8JytJlEqi0zFWNYVDmCEEUtBLAZuTvkbn3_M5gQVeuCNk2DnemHoGQpZAawN-YHo_Z9CN5YtfWuRb9TFNSenDqQUyM5RVUp1T-58W5-fDBUralPV0dUo3571DFobKzHTrtwsmVjdJED-wPoWnn2</recordid><startdate>1998</startdate><enddate>1998</enddate><creator>DAVIES, C. W. H</creator><creator>LOK, S</creator><creator>DAVIES, R. J. O</creator><general>American Lung Association</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>1998</creationdate><title>The systemic fibrinolytic activity of intrapleural streptokinase</title><author>DAVIES, C. W. H ; LOK, S ; DAVIES, R. J. O</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c333t-ada7dfed8bea04df8773f007b8b65e82a046f4af27a1cf3eb33a8b5a0668d6603</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Drainage</topic><topic>Drug Monitoring</topic><topic>Empyema, Pleural - drug therapy</topic><topic>Empyema, Pleural - microbiology</topic><topic>Female</topic><topic>Fibrinolysis - drug effects</topic><topic>Fibrinolytic Agents - therapeutic use</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Partial Thromboplastin Time</topic><topic>Pharmacology. Drug treatments</topic><topic>Pleural Effusion - drug therapy</topic><topic>Pleural Effusion - microbiology</topic><topic>Pleurodesis</topic><topic>Prothrombin Time</topic><topic>Respiratory system</topic><topic>Streptokinase - therapeutic use</topic><topic>Thrombin Time</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>DAVIES, C. W. H</creatorcontrib><creatorcontrib>LOK, S</creatorcontrib><creatorcontrib>DAVIES, R. J. O</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of respiratory and critical care medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>DAVIES, C. W. H</au><au>LOK, S</au><au>DAVIES, R. J. O</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The systemic fibrinolytic activity of intrapleural streptokinase</atitle><jtitle>American journal of respiratory and critical care medicine</jtitle><addtitle>Am J Respir Crit Care Med</addtitle><date>1998</date><risdate>1998</risdate><volume>157</volume><issue>1</issue><spage>328</spage><epage>330</epage><pages>328-330</pages><issn>1073-449X</issn><eissn>1535-4970</eissn><abstract>Intrapleural fibrinolytics probably improve the drainage of loculated pleural effusions and empyemas. Studies of crude indices of systemic coagulation suggest this effect is accompanied by little systemic fibrinolysis, but few studies have assessed this in detail. This study examines the systemic fibrinolytic activity of two intrapleural streptokinase (IPSK) regimes in detail. Eight patients received a single dose of 250,000 IU IPSK, and a further eight received serial doses of 250,000 IU IPSK every 12 h for 3 d (total dose: 1.5 million IU). Each dose was retained in the pleural cavity for 2 h. Venous blood for prothrombin time, activated partial thromboplastin time, thrombin time, fibrinogen, and D-dimers due to fibrin degradation were measured before any IPSK. These end points were then remeasured 24 h after IPSK in the single-dose group and after 24, 48, and 72 h in the group receiving serial doses. There were no physiologic or statistical differences in any of the indices after administration of IPSK. IPSK administered up to a dose of 1.5 million IU does not cause significant activation systemic fibrinolysis in humans.</abstract><cop>New York, NY</cop><pub>American Lung Association</pub><pmid>9445316</pmid><doi>10.1164/ajrccm.157.1.97-03094</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1073-449X |
| ispartof | American journal of respiratory and critical care medicine, 1998, Vol.157 (1), p.328-330 |
| issn | 1073-449X 1535-4970 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_79672000 |
| source | MEDLINE; American Thoracic Society (ATS) Journals Online; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Journals@Ovid Complete |
| subjects | Adult Aged Aged, 80 and over Biological and medical sciences Drainage Drug Monitoring Empyema, Pleural - drug therapy Empyema, Pleural - microbiology Female Fibrinolysis - drug effects Fibrinolytic Agents - therapeutic use Humans Male Medical sciences Middle Aged Partial Thromboplastin Time Pharmacology. Drug treatments Pleural Effusion - drug therapy Pleural Effusion - microbiology Pleurodesis Prothrombin Time Respiratory system Streptokinase - therapeutic use Thrombin Time |
| title | The systemic fibrinolytic activity of intrapleural streptokinase |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T13%3A11%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20systemic%20fibrinolytic%20activity%20of%20intrapleural%20streptokinase&rft.jtitle=American%20journal%20of%20respiratory%20and%20critical%20care%20medicine&rft.au=DAVIES,%20C.%20W.%20H&rft.date=1998&rft.volume=157&rft.issue=1&rft.spage=328&rft.epage=330&rft.pages=328-330&rft.issn=1073-449X&rft.eissn=1535-4970&rft_id=info:doi/10.1164/ajrccm.157.1.97-03094&rft_dat=%3Cproquest_cross%3E79672000%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=79672000&rft_id=info:pmid/9445316&rfr_iscdi=true |